Treatment of psoriasis with interleukin-12/23 monoclonal antibody: A systematic review

European Journal of Dermatology

Volumn 22, Issue 1, 2012, Pages 72-82

  Wu, Yan ^a   Chen, Jing ^b   Li, Yuan Hong ^a   Ma, Guo Zhang ^a   Chen, John Z S ^c   Gao, Xing Hua ^a   Chen, Hong Duo ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c Sheftel Associates Dermatology   (United States)

Author keywords

IL 12 23 monoclonal antibody; Meta analysis; Psoriasis; Randomized controlled trials; Systematic review; Ustekinumab

Indexed keywords

ETANERCEPT; INTERLEUKIM 12/23 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BRAIN INFARCTION; BRONCHITIS; CARDIOVASCULAR DISEASE; CELLULITIS; CORONARY ARTERY DISEASE; COUGHING; DIARRHEA; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEART FAILURE; HEART INFARCTION; HERNIA; HUMAN; INFECTION; INFLUENZA; INJECTION SITE REACTION; INJURY; LOW DRUG DOSE; MYALGIA; NAUSEA; NEOPLASM; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; PSORIASIS; PURPURA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN CANCER; SYSTEMATIC REVIEW; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-12 SUBUNIT P40; PSORIASIS;

EID: 84863233380     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1559     Document Type: Article

References (24)

1. Kauffman CL, Aria N, Toichi E, et al. A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis. J Invest Dermatol 2004; 123:1037-44.
2. Bilac C, Ermertcan AT, Bilac DB, et al. The relationship between symptoms and patient characteristics among psoriasis patient. Indian J Dermatol Venereol Leprol 2009; 75: 551.
3. Eder L, Chandran V, Shen H, et al. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res 2011; 63:619-22.
4. Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management 2010;6:123-41.
5. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-61.
6. Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg 2004;8:310-20.
7. Somani AK, Yang MF, Cooper KD, et al. Cytokines and psoriasis. When cytokines become "pathokines". G Ital Dermatol Venereol 2007; 142:679-90.
8. Kimball AB, Gordon KB, Langley RG, et al. Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Arch Dermatol 2008;144:200-7.
9. Tesmer LA, Lundy SK, Sarkar S, et al. Th17 cells in human disease. Immunol Rev 2008;223:87-113.
10. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-87.
11. Yawalkar N, Karlen S, Hunger R, etal. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998; 111: 1053-7.
12. Hong K, Chu A, Ludviksson BR, et al. IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999; 162: 7480-91.
13. Lee E, Trepicchio WL, Oestreicher JL, etal. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
14. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration 2009. Available from www. cochrane-handbook. org.
15. Review Manager (RevMan) [Computer program]. Version 5.0.25 for Windows. Oxford,England: The Cochrane Collaboration; 2010.
16. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-74.
17. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
18. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010;63:457-65.
19. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. British Journal of Dermatology 2010; 162:137-46.
20. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. N Engl J Med 2010; 362:118-28.
21. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-40.
22. Krueger GG, Langley RG, Leonardi C, et al. A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis. N Engl J Med 2007; 356:580-92.
23. Scanlon JV, Exter BP, Steinberg M, et al. Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis. Ann Pharma-cother 2009; 43: 1456-65.
24. Papp KA. Monitoring biologics for the treatment of psoriasis. Clin Dermatol 2008;26:515-21.